Cynata Therapeutics release its Appendix 4E and Annual Report

Cynata Therapeutics release its Appendix 4E and Annual Report

Cynata Therapeutics has released its Appendix 4E and Annual Report, reflecting a year of strong momentum and significant progress across its clinical pipeline. As Independent Chair, Dr Geoff Brooke states, “Cynata is entering what I believe will be the most pivotal year in our history. Within the next 12 months, we expect results from three clinical trials, each with the potential to transform treatment in large, high-need markets and significantly enhance the Company’s value.”

Key highlights this year include:
– 1 clinical trial completed, with three more progressing towards results in FY26
– Positive efficacy data in DFU and preclinical models of pulmonary fibrosis & heart disease
– Osteoarthritis trial nearing completion (results expected early 2026)
– Strong funding runway through mid-2026, supporting all key clinical readouts

BioScience Managers champions Cynata Therapeutics and its groundbreaking cell therapy solutions in late-stage clinical development, paving the way for treatments to address some of the world’s most pressing medical challenges.